IL10 and myeloid sarcoma: Interestingly, the anti-inflammatory cytokine IL-10 was significantly reduced at 6 months, 12 months, and 24 months post-AHSCT compared to baseline levels in MS patients (Figure 2C), whereas both IL-4 and IL-2 were only significantly reduced at 6 months post-AHSCT.